Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for copd
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
> > Family determinants as a risk factor for chronicobstructivepulmonarydisease: a systematic review Ana Inês Vasques Martins, Susana Maria Vasques, Paulo Santos Resumo Introduction: Chronicobstructivepulmonarydisease (COPD) is a preventable respiratorydisease, with repercussion in quality of life. Worldwide COPD is a leading cause of mortality. Cigarette smoking is the most debated risk factor, but it’s important to identify other determinants at stake. Family context and behaviors have an impact (...) not contain any of the other studies included. Conclusions: Little evidence is available on the effect of family determinants in the development of COPD. The studies reported an association between COPD and low socioeconomic status and low education and an interaction with childhood maltreatment. Keywords: chronicobstructivepulmonarydisease, family, risk factors Palavras-chave chronicobstructivepulmonarydisease; family; risk factors Texto Completo: DOI: Apontadores Não há apontadores. Copyright (c
of TCM Cheng-xiang Wang Beijing University of TCM Mei Han Corresponding Author DOI: License: This work is licensed under a CC BY 4.0 License. View the published version . Abstract Objective: To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronicobstructivepulmonarydisease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed (...) The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronicobstructivepulmonarydisease: a meta-analysis and system review The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronicobstructivepulmonarydisease: a meta-analysis and system review | Research Square Browse Tools & Services Your Cart See the published version of this article
Effect of smoking cessation on CT imaging in patients with ChronicObstructivePulmonaryDisease: A systematic review Effect of smoking cessation on CT imaging in patients with ChronicObstructivePulmonaryDisease: A systematic review | medRxiv Search for this keyword Effect of smoking cessation on CT imaging in patients with ChronicObstructivePulmonaryDisease: A systematic review Daryl Cheng , Siddharth Agarwal , Joseph Jacob , John R Hurst doi: https://doi.org/10.1101/2020.02.11.20022129 (...) expiratory volume/1s (FEV 1 ) over time. The need for new drugs to modify the progression of COPD is well recognised. We hypothesised that changes on CT in relation to smoking cessation may relate to changes in response to disease-modifying drugs, and therefore as a novel quantitative biomarker of drug efficacy. CT biomarkers of emphysema and airway wall thickness are increasingly used in research, but there has not been a systematic appraisal of the evidence to assess how these biomarkers evolve
Oxygen therapy in the pre-hospital setting for acute exacerbations of chronicobstructivepulmonarydisease. Chronicobstructivepulmonarydisease (COPD) is a global leading cause of morbidity and mortality, characterised by acute deterioration in symptoms. During these exacerbations, people are prone to developing alveolar hypoventilation, which may be partly caused by the administration of high inspired oxygen concentrations.To determine the effect of different inspired oxygen concentrations (...) ("high flow" compared to "controlled") in the pre-hospital setting (prior to casualty/emergency department) on outcomes for people with acute exacerbations of COPD (AECOPD).The Cochrane Airways Group Specialised Register, reference lists of articles and online clinical trial databases were searched. Authors of identified randomised controlled trials (RCTs) were also contacted for details of other relevant published and unpublished studies. The most recent search was conducted on 16 September 2019.We
COVID-19. Signpost to charities (such as the British Lung Foundation) and support groups (such as NHS Volunteer Responders), and UK government guidance on the mental health and wellbeing aspects of COVID-19. 1.2 Explain to patients with chronicobstructivepulmonarydisease (COPD), and their families and carers, that they are at increased risk of severe illness from COVID-19. 1.3 Be aware that the NICE guideline on chronicobstructivepulmonarydisease in over 16s defines severe airflowobstruction (...) , and they should take appropriate precautions such as: • performing airway clearance techniques in a well-ventilated room • performing airway clearance techniques away from other family members if possible • advising other family members not to enter the room until enough time has passed for aerosols to clear. Find out more from UK government guidance on COVID-19: infection prevention and control. COVID-19 rapid guideline: community-based care of patients with chronicobstructivepulmonarydisease (COPD
: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronicobstructivepulmonarydisease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion. Objectives: To determine the safety and impact of TLD on respiratory adverse events. Methods: We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale (...) treated with TLD combined with optimal pharmacotherapy had fewer study-defined respiratory adverse events, including hospitalizations for COPD exacerbation.Clinical trial registered with www.clinicaltrials.gov ( ). Keywords: anticholinergic; bronchoscopy; chronicobstructivepulmonarydisease; nerves; targeted lung denervation. Figures Figure 1. 5 Respiratory adverse events between 3... Figure 1. 13 Respiratory adverse events between 3 and 6.5 months after bronchoscopy for the... Figure 1. Respiratory
Chronicobstructivepulmonarydisease: Mucolytics Mucolytics | Prescribing information | Chronicobstructivepulmonarydisease | CKS | NICE Search CKS… Menu Mucolytics Chronicobstructivepulmonarydisease: Mucolytics Last revised in November 2019 Mucolytics Which mucolytics can be prescribed? Carbocisteine and acetylcysteine are the oral mucolytics licensed for use in people with chronicobstructivepulmonarydisease. For carbocisteine the manufacturer recommends a starting dose of 2250 mg (...) in divided doses, reducing to 1500 mg daily in divided doses when a satisfactory response is obtained. For acetylcysteine, the manufacturer recommends a dose of 1 effervescent tablet of 600 mg once daily. [ ] [ ] [ ] What contraindications and cautions are important with carbocisteine? Do not prescribe carbocisteine to: People with active peptic ulceration. People with asthma or respiratory failure. Women who are pregnant or breastfeeding. Prescribe carbocisteine with caution to: People with a history
Chronicobstructivepulmonarydisease: Inhaled corticosteroids Inhaled corticosteroids | Prescribing information | Chronicobstructivepulmonarydisease | CKS | NICE Search CKS… Menu Inhaled corticosteroids Chronicobstructivepulmonarydisease: Inhaled corticosteroids Last revised in November 2019 Inhaled corticosteroids What inhaled corticosteroids are available for COPD, and what dose should I prescribe? Inhaled corticosteroids (ICS) should be prescribed in combination with a long-acting (...) bronchodilator in people with chronicobstructivepulmonarydisease (COPD). The NICE guideline on COPD [ ] recommends that where combination therapy with long-acting bronchodilators and ICS is being considered, clinicians should be aware of, and discuss with the person, the risk of adverse effects including an increased risk of pneumonia (which may require hospitalization). Inhaled corticosteroid preparations licensed for the management of COPD are available as combination products. They include: Formoterol
, see the CKS topic on . Pneumothorax. Acute heart failure. Pleural effusion. Cardiac ischaemia or arrhythmia. For more information, see the CKS topics on and . Lung cancer. For more information, see the CKS topic on . Upper airwayobstruction. Basis for recommendation The information on symptoms and differential diagnosis of an acute exacerbation of chronicobstructivepulmonarydisease (COPD) is based on expert opinion in clinical guidelines Management of COPD exacerbations: a European Respiratory (...) and change in sputum colour. Other reported symptoms may include: Increased wheeze and chest tightness. Upper respiratory tract symptoms (for example cold or sore throat). Reduced exercise tolerance. Ankle swelling. Increased fatigue. Acute confusion. What else might it be? Conditions which may present with similar symptoms to an acute exacerbation of chronicobstructivepulmonarydisease (COPD) include : Pneumonia. For more information, see the CKS topic on . Pulmonary embolism. For more information
Chronicobstructivepulmonarydisease: Beta-2 agonists Beta-2 agonists | Prescribing information | Chronicobstructivepulmonarydisease | CKS | NICE Search CKS… Menu Beta-2 agonists Chronicobstructivepulmonarydisease: Beta-2 agonists Last revised in November 2019 Beta-2 agonists Beta-2 agonists act directly on beta-2 receptors, causing smooth muscle relaxation and dilatation of the airways . Short-acting beta-2 agonists (SABAs) such as salbutamol and terbutaline are used for immediate (...) events may be higher in people with a predisposition to arrhythmias and in people with pre-existing cardiovascular disease, or hypertension. For some pressurised metered-dose inhalers there is a risk of airwayobstruction from aspiration of loose objects. [ ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ] What drug interactions are important with beta-2 agonists? Corticosteroids, diuretics, and theophylline — monitor potassium levels. Beta-2 agonists can cause hypokalaemia (particularly at high doses), and this can
is identified. Spirometry Post-bronchodilator spirometry should be performed and interpreted by an appropriately trained health professional to confirm the diagnosis of chronicobstructivepulmonarydisease (COPD). Spirometry should be carried out 15–20 minutes after the person has inhaled a short-acting bronchodilator (for example 400 micrograms salbutamol delivered via a spacer device — local protocols may vary). Airflowobstruction is defined as a post bronchodilator ratio of forced expiratory volume (...) [ ]. Assessment The recommendations on assessment of a person with suspected COPD are based on the clinical guidelines Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap [ ], COPD-X: concise guide for primary care [ ], Chronicobstructivepulmonarydisease (COPD): best practice guide [ ], Global initiative for chronicobstructivelungdisease (GOLD). Global strategy for the diagnosis, management, and prevention of chronicobstructivepulmonarydisease. 2019 report [ ], Chronicobstructive
ChronicobstructivepulmonarydiseaseChronicobstructivepulmonarydisease | Topics A to Z | CKS | NICE Search CKS… Menu ChronicobstructivepulmonarydiseaseChronicobstructivepulmonarydisease Last revised in November 2019 Chronicobstructivepulmonarydisease (COPD) is a treatable (but not curable) and largely preventable lungdisease. Diagnosis Management Prescribing information Background information Chronicobstructivepulmonarydisease - Summary Chronicobstructivepulmonarydisease (...) (COPD) is a common, treatable (but not curable) and largely preventable lung condition. It is characterised by persistent respiratory symptoms and airflowobstruction which is usually progressive and not fully reversible. Tobacco smoking is a major risk factor for the development of COPD. Complications include reduced quality of life and increased morbidity and mortality. Diagnosis of COPD is based on the presence of typical clinical features supported by spirometry. COPD should be suspected
Chronicobstructivepulmonarydisease: Antibiotics Antibiotics | Prescribing information | Chronicobstructivepulmonarydisease | CKS | NICE Search CKS… Menu Antibiotics Chronicobstructivepulmonarydisease: Antibiotics Last revised in November 2019 Antibiotics Azithromycin Contraindications and cautions Do not prescribe azithromycin in people: With severe hepatic impairment. Prescribe azithromycin with caution in people: Who may be predisposed to prolongation of the QT interval. For example (...) and cautions Do not prescribe amoxicillin to: People with a true penicillin hypersensitivity — gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin. Prescribe amoxicillin with caution in people with: Hypersensitivity to cephalosporins. Chronic kidney disease (CKD) — reduce the dose of amoxicillin. Adverse effects Gastrointestinal — nausea and diarrhoea (common), vomiting (uncommon). Very rarely: antibiotic-associated colitis (including
Feb 1];6:276-83. Available from: Introduction Chronicobstructivepulmonarydisease (COPD) is a common, preventable, and treatable disease, which is characterized by persistent respiratory symptoms and airflow restriction due to exposure to toxic particles or gas. Acute exacerbation of COPD (AECOPD) refers to the continuous deterioration of the patient's condition beyond daily life and the need to change the basic medication. Usually, it is manifested as short-term cough, expectoration, shortness (...) that the efficacy of experimental group in the treatment of AECOPD is better than control group. Due to the limitation of the number and quality of included studies, this conclusion needs more high quality studies to confirm. "> Users Online: 38 REVIEW ARTICLE Year : 2020 | Volume : 6 | Issue : 3 | Page : 276-283 Systematic review and meta-analysis of shenfu injection on treating acute exacerbation of chronicobstructivepulmonarydisease 1 , 2 , 2 , 2 , 2 1 Institute of Basic Research in Clinical Medicine
and intervention type in chronicobstructivepulmonarydisease patients: a systematic review and meta-analysis. Int J Nurs Stud 2019;92:1–15. Implications for practice and research Monitoring patients’ health remotely at home using technology has been gaining in popularity for a number of years. Evidence suggests that tele-monitoring may have the potential to reduce emergency room visits and hospitalisation for patients with chronicobstructivepulmonarydisease (COPD), particularly those with high disease (...) severity. More rigorously conducted trials of tele-monitoring in patients with COPD are required to determine clinical and cost-effectiveness. Context COPD is a long-term, debilitating, respiratory condition that impacts the lives of millions of people worldwide. Poor management of COPD can lead to hospital admissions, increased healthcare costs and poorer outcomes for patients and their families. 1 A range of interventions are used to aid self-management of this disease including technologies
. The manufacturer had no other role in any part of the trial.To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000820/crp-testing-safely-reduces-antibiotic-use-for-copd-flare-ups.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. (...) C reactive protein testing in general practice safely reduces antibiotic use for flare-ups of COPD. The studyButler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med 2019;381:111-20.This research was funded by the NIHR Technology Assessment Programme (project number 12/33/12). The testing machines used in the study were loaned to researchers by the manufacturer, who also provided training on their use
Metoprolol for the Prevention of Acute Exacerbations of COPD. Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronicobstructivepulmonarydisease (COPD), but these findings have not been confirmed in randomized trials.In this prospective, randomized trial, we assigned patients between the ages of 40 and 85 years who had COPD to receive either a beta-blocker (extended-release metoprolol) or placebo. All (...) the patients had a clinical history of COPD, along with moderate airflowlimitation and an increased risk of exacerbations, as evidenced by a history of exacerbations during the previous year or the prescribed use of supplemental oxygen. We excluded patients who were already taking a beta-blocker or who had an established indication for the use of such drugs. The primary end point was the time until the first exacerbation of COPD during the treatment period, which ranged from 336 to 350 days, depending
Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronicobstructivepulmonarydisease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks (...) in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.We conclude that in AATD patients with severe COPD
, and Blood Institute. COPD national action plan. Washington, D.C.: U.S. Department of Health and Human Services; 2017 [accessed 2018 Jul 6]. Available from: . van Agteren JE, Hnin K, Grosser D, Carson KV, Smith BJ. Bronchoscopic lung volume reduction procedures for chronicobstructivepulmonarydisease. Cochrane Database Syst Rev. 2017;2:CD012158. - - Kaplan RM, Ries AL. Health-related quality of life in emphysema. Proc Am Thorac Soc. 2008;5:561–566. - - Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto (...) similar articles Cited by 1 PubMed Central articles NS Hopkinson. Am J Respir Crit Care Med 200 (11), 1329-1331. 2019. PMID 31560561. References Wheaton AG, Cunningham TJ, Ford ES, Croft JB Centers for Disease Control and Prevention (CDC) Employment and activity limitations among adults with chronicobstructivepulmonarydisease: United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64:289–295. - - U.S. Department of Health and Human Services, National Institutes of Health and National Heart, Lung
of Canada, Richmond Hill, Ontario, Canada; j Institut Universitaire de Cardiologie et de Pneumologie de Qu ebec, Universit e Laval, Qu ebec, Quebec, Canada; k Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; l Respiratory Research Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada ABSTRACT In this guideline update, we highlight important and new findings related to pharmacological therapy of chronicobstructivepulmonarydisease (COPD (...) corticost eroïde en inhalation (CSI)/BALA, sauf chez les patients ayant d ej a subi des exac- erbations et dont le nombre d’ eosinophiles de sang p eriph erique est elev e. Il n’y a pas lieu de recourir a la monoth erapie de CSI; lorsqu’ils sont indiqu es, les CSI doivent ^ etre utilis es uniquement KEYWORDS Chronicobstructivepulmonarydisease; COPD; guideline; pharmacotherapy; Canadian Thoracic Society; CTS CONTACT Jean Bourbeau email@example.com Respiratory Epidemiology and Clinical Research